In vitro treatment of RRMS patients’ T cells with antiIL-6R monoclonal antibody caused a decrease in IL-17 production and an increase in IL-10 production by activated CD4+ T cells but didn’t affect CD8+ T cells. Here, CD4 is linked to relapsing-remitting multiple sclerosis.